COMPANY

Alkahest

HQ: San Carlos, CA source · alkahest.com ↗

Alkahest, a Grifols subsidiary, is a research and drug discovery company mining the deepest layers of plasma knowledge to inform the development of potential therapies and solutions for patients. From company website Source · Oct 12, 2026

Keywords: End-Stage Renal Disease Parkinson Disease Wet Age-related Macular Degeneration Postoperative Recovery Diabetic Retinopathy Bullous Pemphigoid Cognitive Impairment Neovascular Age-related Macular Degeneration Alzheimer Disease Mild to Moderate Alzheimer Disease Severe Alzheimer Disease AKST4290 GRF6021 GRF6019 ALK4290 AKST1210

Location: San Carlos, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

12Trials (company is sponsor)

Timeline

Aug 17, 2021 Trial start Phase 2: A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI) source ↗
Mar 11, 2021 Trial start Not phased (device or behavioral study): Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis source ↗
Apr 28, 2020 Trial start Not phased (device or behavioral study): A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment source ↗
Jan 30, 2020 Trial start Phase 2: A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid source ↗
Jan 28, 2020 Trial start Phase 2: A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD source ↗
Jan 16, 2020 Trial start Phase 2: Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment source ↗
Jul 12, 2019 Trial start Phase 2: A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty source ↗
Jan 15, 2019 Trial start Phase 2: A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease source ↗
Nov 12, 2018 Trial start Phase 2: A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment source ↗
Apr 20, 2018 Trial start Phase 2: Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration source ↗
Apr 16, 2018 Trial start Phase 2: A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease source ↗
Apr 4, 2018 Trial start Phase 2: Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration source ↗

Clinical trials (lead sponsor) 12

Record	Title	Phase	Status	Start	Primary completion
NCT03981419	A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty	Phase 2	Completed	Jul 12, 2019	Jan 23, 2021 (actual)
NCT05038020	A Study to Evaluate the Efficacy of Oral AKST4290 in Participants With Moderately Severe to Severe Diabetic Retinopathy (CAPRI)	Phase 2	Terminated	Aug 17, 2021	Dec 9, 2021 (actual)
NCT04985383	Study to Compare Safety and Tolerability of AKST1210 Column at 2 Blood Flow Rates in Subjects With ESRD on Hemodialysis	Not phased (device or behavioral study)	Completed	Mar 11, 2021	Sep 1, 2021 (actual)
NCT04499235	A Study to Assess the Therapeutic Effect and Safety of Adjunctive AKST4290 in Subjects With Bullous Pemphigoid	Phase 2	Terminated	Jan 30, 2020	Mar 29, 2021 (actual)
NCT04527328	A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment	Not phased (device or behavioral study)	Completed	Apr 28, 2020	Jun 4, 2021 (actual)
NCT04331730	A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD	Phase 2	Completed	Jan 28, 2020	Aug 19, 2021 (actual)
NCT04369430	Study Assessing Efficacy and Safety of AKST4290 in Subjects With Parkinson's Disease on Stable Dopaminergic Treatment	Phase 2	Completed	Jan 16, 2020	Feb 11, 2021 (actual)
NCT03713957	A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment	Phase 2	Completed	Nov 12, 2018	Jul 20, 2020 (actual)
NCT03520998	A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease	Phase 2	Completed	Apr 16, 2018	May 24, 2019 (actual)
NCT03765762	A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease	Phase 2	Completed	Jan 15, 2019	Dec 17, 2019 (actual)
NCT03558074	Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration	Phase 2	Completed	Apr 20, 2018	Nov 29, 2018 (actual)
NCT03558061	Evaluate the Effects and Safety of ALK4290 in Patients With Newly Diagnosed Wet Age-Related Macular Degeneration	Phase 2	Completed	Apr 4, 2018	Nov 18, 2018 (actual)